Tissue-Engineered Trachea (TET)
Long-segment tracheal stenosis/tumors/trauma
Phase 1Active
Key Facts
About Videregen
Videregen is a clinical-stage biotechnology company pioneering tissue-engineered airway replacements. Its core technology involves a proprietary, biocompatible scaffold that is seeded with a patient's own stem cells to create a personalized, living implant designed to integrate with native tissue. The company's lead product candidate, a tissue-engineered trachea, is advancing through clinical development to address a significant unmet need in reconstructive surgery. Founded in 2012 and based in Manchester, Videregen operates as a private company, leveraging strategic partnerships and grant funding to advance its pipeline.
View full company profile